
Claims

1. Use of a 1-phenyl-3-dimethylamino-propane compound according to the general Formula I



I

wherein X is selected from OH, F, Cl, $OC(O)CH_3$ or H, preferably OH, F, $OC(O)CH_3$ or H,

and/or

R^1 is selected from C_{1-4}-alkyl, saturated and unsubstituted, branched or unbranched; preferably CH_3, C_2H_5, C_4H_9 or t-butyl, in particular CH_3 or C_2H_5,

and/or

R^2 and R^3 independently of one another are selected from H, C_{1-4}-alkyl, saturated and unsubstituted, branched or unbranched; preferably H, CH_3, C_2H_5, i-propyl or t-butyl, in particular H or CH_3, preferably R^3 = H,

or

R^2 and R^3 together form a C_{5-6}-cycloalkyl radical, saturated or unsaturated, unsubstituted or monosubstituted or polysubstituted, preferably saturated and unsubstituted, in particular cyclohexyl,

and/or

R^9 to R^{13}, in which three or four of the radicals R^9 to R^{13} must correspond to H, are independently of one another selected from H, Cl, F, OH, CF_2H, CF_3 or C_{1-4}-alkyl, saturated and unsubstituted, branched or unbranched; OR^{14} or SR^{14}, where R^{14} is selected from C_{1-3}-alkyl, saturated and unsubstituted, branched or unbranched;

preferably H, Cl, F, OH, CF_2H, CF_3, OCH_3 or SCH_3

or R^{12} and R^{11} form a 3,4-OCH=CH ring,

in particular

if R^9, R^{11} and R^{13} correspond to H, one of R^{10} and R^{12} also corresponds to H, while the other is selected from:

Cl, F, OH, CF_2H, CF_3, OR^{14} or SR^{14}, preferably OH, CF_2H, OCH_3 or SCH_3,

or

if R^9 and R^{13} correspond to H and R^{11} corresponds to OH, OCH_3, Cl or F, preferably to Cl, then one of R^{10} and R^{12}

also corresponds to H, while the other corresponds to OH, OCH_3, Cl or F, preferably Cl,

or

if R^9, R^{10} ,R12 and R^{13} correspond to H, R^{11} is selected from CF_3, CF_2H, Cl or F, preferably F,

or

if R^{10}, R^{11} and R^{12} correspond to H, one of R^9 and R^{13} also corresponds to H, while the other is selected from OH, OC_2H_5 or OC_3H_7,

optionally in the form of their racemates, their pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of the stereoisomers, in particular of the enantiomers or diastereomers, in an arbitrary mixture ratio; in the prepared form or in the form of their acids or their bases or in the form of their salts, in particular the physiologically compatible salts, or in the form of their solvates, in particular the hydrates;

---


for the production of a medicament for treating rheumatoid, preferably rheumatoid arthritic, very preferably chronic rheumatoid arthritic pain;

with the proviso that the medicament is not a dosage form comprising at least one form of tapentadol and at least one opioid antagonist wherein the said

antagonist improves the efficacy and or reduces the side effects of tapentadol;

and with the proviso that the medicament is not a pharmaceutical composition comprising a slow release tapentadol and at least one pharmaceutically acceptable carrier, and a second active agent, wherein the second active agent is tramadol, a GABA analogues or an NSAID.

2. Use according to claim 1, characterised in that the compound of the Formula I where R^3 = H is present in the form of the diastereomers with the relative configuration Ia



Ia

is used in particular in mixtures with a higher proportion of this diastereomer compared to the other diastereomer, or is used as pure diastereomer.

3. Use according to one of claims 1 and 2, characterised in that a compound of the Formula I selected from the following group is used:

- (2RS,3RS)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol,

- (+)-(2R, 3R)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol, and
- (2R,3R)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol,
- (-)-(2S,3S)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol,
- (2S,3S)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol,
- (2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2methyl-pentan-3-ol,
- (2 RS,3RS)-3-(3-difluoromethylphenyl)-1-dimethylamino-2methyl-pentan-3-ol,
- (2RS, 3RS)-1-dimethylamino-2-methyl-3-(3-methylsulfanylphenyl)-pentan-3-ol,
- (3RS)-1-dimethylamino-3-(3-methoxyphenyl)-4,4-dimethylpentan-3-ol,
- (2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol,
- (1RS, 2RS)-3-(3-dimethylamino-1-hydroxy-1 ,2-dimethylpropyl)-phenol,
- (+)-(1R, 2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethylpropyl)-phenol,
- (1R, 2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethylpropyl)phenol,
- (-)-(1S, 2S)-3-(3-dimethylamino-1-hydroxy-1,2-dimethylpropyl)-phenol,
- (1S, 2S)-3-(3-dimethylamino-1-hydroxy-1,2-dimethylpropyl)phenol,
- (RS, RS)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol,
- (-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-

methylpropyl)phenol,

- (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol,
- (+)-(1S, 2S)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol,
- (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol,
- (+)-(1R, 2R)-acetic acid-3-dimethylamino-1-ethyl-1-(3-methoxy-phenyl)-2-methyl propyl ester,
- (2RS, 3RS)-3-(4-chlorophenyl)-1-dimethylamino-2-methylpentan-3-ol,
- (+)-(2R, 3R)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol,
- (2RS, 3RS)-4-dimethylamino-2-(3-methoxyphenyl)-3methylbutan-2-ol and
- (+)-(2R, 3R)-4-dimethylamino-2-(3-methoxyphenyl)-3-methylbutan-2-ol,

preferably as the hydrochloride,

in particular

- (RS, RS)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol,
- (-)-(1 R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl) phenol,
- (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl) phenol,
- (-)-(1S, 2S)-3-(3-dimethylamino-1-ethyl-2-methylpropyl) phenol,
- (1S, 2S)-3-(3-dimethylamino-1-ethyl-2-

methylpropyl) phenol,

preferably

- (-)-(1 R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol,
- (1 R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl) phenol.

4. Use of (1RS, 2RS)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol, preferably (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol, most preferably as the hydrochloride salt, for the preparation of a medicament for treating rheumatoid, preferably rheumatoid arthritic, very preferably chronic rheumatoid arthritic pain;

with the proviso that the medicament is not a dosage form comprising at least one form of tapentadol and at least one opioid antagonist wherein said antagonist improves the efficacy and or reduces the side effects of tapentadol; and

with the proviso that the medicament is not a pharmaceutical composition comprising a slow release tapentadol and at least one pharmaceutically acceptable carrier, and a second active agent, wherein the second active agent is tramadol, a GABA analogues or an NSAID.

5. Use of a compound of the Formula I according to any one of claims 1-3, preferably of the Formula Ia, most preferably the compound (1RS, 2RS)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol, most particularly

preferably (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol, for treating rheumatoid, preferably rheumatoid arthritic, very preferably chronic rheumatoid arthritic pain.

6. Use of a compound according to any one of claims 1-3, preferably (1RS, 2RS)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol, most preferably (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol, for treating rheumatoid, preferably rheumatoid arthritic, very preferably chronic rheumatoid arthritic pain.